Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06638294 · ClinicalTrials.gov registry record

Study in Patients With Breast Cancer Leptomeningeal Metastasis

A clinical trial of Leptomeningeal Metastasis of Breast Cancer, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.

Recruiting
Registry status
30
Enrollment target
2
Study locations

NCT06638294 is a study of Leptomeningeal Metastasis of Breast Cancer that is actively recruiting participants, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 30 participants. The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06638294, a study of Leptomeningeal Metastasis of Breast Cancer, is actively recruiting participants, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.

RECRUITING
Registry status
30 participants
Enrollment target
2
Study locations

Study Summary

Traditional clinical trials in patients with breast cancer leptomeningeal disease (LMD) are challenging as patients often have a rapidly progressive course and prognosis is poor, making meeting standard eligibility difficult. Furthermore, there is limited information about the biology of LMD. The investigators thus propose a study that is as inclusive as possible, which will allow the investigators to collect biospecimens and clinical outcomes to learn more about LMD biology, but still potentially provide benefit for patients, by providing patients rapid diagnostics and multi-disciplinary treatment recommendations.

Study Locations (2)

District of Columbia

  • Sibley Memorial Hospital - Washington D.C.

Maryland

  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins - Baltimore

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2024-11-25
Est. Completion 2028-12

What the Registry Record Tells You About NCT06638294

The ClinicalTrials.gov registry entry for NCT06638294 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Leptomeningeal Metastasis of Breast Cancer appearing as the primary indexed condition, and to 0 interventions.

NCT06638294 reports 2 study locations spanning 2 distinct geographic areas - top geographies include District of Columbia, Maryland.

Frequently Asked Questions

What is clinical trial NCT06638294 about?

NCT06638294 is a clinical study titled "Study in Patients With Breast Cancer Leptomeningeal Metastasis". Traditional clinical trials in patients with breast cancer leptomeningeal disease (LMD) are challenging as patients often have a rapidly progressive course and prognosis is poor, making meeting standard eligibility difficult. Furthermore, there is limited information about the biology of LMD. The in...

What is the current status of trial NCT06638294?

This trial is currently recruiting. The enrollment target is 30 participants. The study started on 2024-11-25. Estimated completion is 2028-12.

What conditions does trial NCT06638294 study?

This clinical trial studies the following conditions: Leptomeningeal Metastasis of Breast Cancer.

Who is sponsoring clinical trial NCT06638294?

This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06638294 being conducted?

This trial has 2 study locations across District of Columbia, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.